Get the Stockscreener App
0.487
0.21%
0.001
After Hours:
.49
0.003
+0.62%
Nkgen Biotech Inc stock is traded at $0.487, with a volume of 56,602.
It is up +0.21% in the last 24 hours and down -30.13% over the past month.
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.
See More
Previous Close:
$0.486
Open:
$0.47
24h Volume:
56,602
Relative Volume:
0.09
Market Cap:
$16.97M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.36%
1M Performance:
-30.13%
6M Performance:
-54.49%
1Y Performance:
-71.01%
1-Day Range:
$0.47
$0.4997
1-Week Range:
$0.4528
$0.5324
52-Week Range:
$0.2026
$4.06
Nkgen Biotech Inc Stock (NKGN) Company Profile
Name
Nkgen Biotech Inc
Sector
Industry
Phone
(949) 396-6830
Address
3001 DAIMLER ST,, SANTA ANA
Compare NKGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.487 | 16.97M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nkgen Biotech Inc Stock (NKGN) Latest News
NKGen Biotech (NYSE:NKGN) Trading Up 9.5% – Time to Buy? - Defense World
Midday Stock Roundup: Alignment Healthcare Rises on Update - Orange County Business Journal
Biotech Drama: Compliance Restored! Big Moves by NKGen Biotech! - Jomfruland.net
NKGen Biotech regains compliance with Nasdaq listing standards - Investing.com
NKGen Biotech secures $4.5M in convertible loan agreement - Investing.com India
NKGen Biotech secures $4.5M in convertible loan agreement By Investing.com - Investing.com Canada
NKGen Biotech (NYSE:NKGN) Shares Down 2.3% – Here’s Why - Defense World
Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024 - Asianet Newsable
NKGen Biotech Awards Stock Options to Executives - TipRanks
Head to Head Survey: HilleVax (NASDAQ:HLVX) versus NKGen Biotech (NYSE:NKGN) - Defense World
NKGen Biotech faces Nasdaq delisting over market value By Investing.com - Investing.com Canada
NKGen Biotech faces Nasdaq delisting over market value - Investing.com
NKGen Biotech Selected as Stalking Horse Bidder for NKMax - GlobeNewswire
NKGen Biotech Secures $18M Bid for NKMax Acquisition, Expanding Global IP Rights - StockTitan
NKGen Biotech faces Nasdaq compliance issue By Investing.com - Investing.com Canada
NKGen Biotech faces Nasdaq compliance issue - Investing.com India
NKGen Biotech Receives Notifications From Nasdaq… - Inkl
NKGen Biotech Receives Notifications From Nasdaq Related to - GlobeNewswire
NKGen Biotech Receives Nasdaq Non-Compliance Notice, Granted Extension for Q3 Filing | NKGN Stock News - StockTitan
OC500 2024: Paul Y. Song - Orange County Business Journal
NKGen Biotech (NYSE:NKGN) versus Relay Therapeutics (NASDAQ:RLAY) Financial Contrast - Defense World
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - PR Newswire
NKGen Flat on Presentation of Alzheimer's Treatment - Baystreet.ca
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - The Manila Times
NKGen Biotech Presents Phase 1/2a Troculeucel Data in - GlobeNewswire
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
NKGen Biotech avoids Nasdaq delisting with regained compliance - Investing.com India
Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket - Benzinga
Dow Falls Over 100 Points; Netflix Posts Upbeat ResultsCatheter Precision (AMEX:VTAK) - Benzinga
Navigating NKGN Stock: NKGen Biotech Inc Journey - The InvestChronicle
Post-Trade Analysis: NKGen Biotech Inc (NKGN) Slides -6.54, Closing at 0.23 - The Dwinnex
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024) - The Manila Times
NKGen Biotech undergoes dilutive stock issuance By Investing.com - Investing.com Canada
NKGen Biotech undergoes dilutive stock issuance - Investing.com India
NKGN stock touches 52-week low at $0.35 amid market challenges - Investing.com Australia
NKGen Biotech Announces Poster Presentations at the 17th - GlobeNewswire
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
Market Watch Highlights: NKGen Biotech Inc (NKGN) Ends on an Upturn Note at 0.40 - The Dwinnex
NKGen Biotech directors resign after a year of service By Investing.com - Investing.com Australia
NKGen Biotech appoints new directors to its board By Investing.com - Investing.com South Africa
NKGen Biotech appoints new directors to its board - Investing.com India
NKGen Biotech Welcomes New Directors and Assigns Committees - TipRanks
Nkgen Biotech Inc Stock (NKGN) Financials Data
There is no financial data for Nkgen Biotech Inc (NKGN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):